Loading…
RAPP
Rapport Therapeutics, Inc.
NASDAQ· Healthcare· Biotechnology
$48.77-4.05%
Key metrics
- Market cap
- $2.34B
- P/E
- —
- Forward P/E
- —
- P/B
- 5.5x
- Dividend yield
- —
- EPS
- -$3.03
- ROE
- -39.96%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 0.97
- 52-week high
- $52.93
- 52-week low
- $14.11
History
How the company evolved, year by year. Revenue and debt come from the annual statements; dividends from the payments themselves, which reach further back.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
About the company
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.
- 84
- Boston, United States
Company description provided by Yahoo Finance.